Tempus AI, Predicta Expand Genomics Test for Blood Cancer
Chicago, Illinois, U.S. | April 15, 2026 Tempus AI, Inc., in collaboration with Predicta Biosciences, has announced the expansion...
hematologic malignancies
Advertisement
AI-NGS Test Detects AML, MDS Relapse Post-Transplant
BRISBANE, Calif., Feb. 12, 2026 — CareDx announced pivotal clinical validation results for AlloHeme, the first AI-powered, next-generation sequencing...
BeOne Medicines’ Sonrotoclax Gets FDA Breakthrough Status
October 13, 2025 | USA – BeOne Medicines, a clinical-stage biopharmaceutical company, announced that its investigational drug Sonrotoclax has...
Tezspire Wins CHMP Backing for Chronic Rhinosinusitis in EU
September 22, 2025 – Brussels, Belgium – AstraZeneca and Amgen announced that the European Medicines Agency’s (EMA) Committee for...
Jaypirca Gains Approval as First Non-Covalent BTK Inhibitor for CLL/SLL
INDIANAPOLIS, September 8, 2025 — Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, has demonstrated a...
Advertisement
